Holen Sie sich die Stockscreener-App
9.4233
1.45%
0.1333
Schlusskurs vom Vortag:
$9.29
Offen:
$9.35
24-Stunden-Volumen:
384.64K
Relative Volume:
0.27
Marktkapitalisierung:
$836.59M
Einnahmen:
$67.48M
Nettoeinkommen (Verlust:
$-278.67M
KGV:
-2.9657
EPS:
-3.1774
Netto-Cashflow:
$-70.70M
1W Leistung:
+7.71%
1M Leistung:
+11.01%
6M Leistung:
-7.24%
1J Leistung:
+62.78%
1-Tages-Spanne:
$9.27
$9.48
1-Wochen-Bereich:
$8.67
$9.48
52-Wochen-Spanne:
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.425 | 824.61M | 67.48M | -278.67M | -70.70M | -3.1774 |
VRTX
Vertex Pharmaceuticals Inc
|
425.09 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
719.00 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.81 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.87 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
316.07 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Lake Street | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Neutral |
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Kura Oncology to Participate in Bank of America Securities Healthcare Conference - GlobeNewswire
Kura Oncology schedules May 12 webcast for Q1 2026 results - Stock Titan
Kura Oncology to Report First Quarter 2026 Financial Results - Yahoo Finance
How The Kura Oncology (KURA) Story Is Evolving After Komzifti Launch And Q4 Reassessment - Yahoo Finance
Five new Kura hires get stock options for 133,750 shares - Stock Titan
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
KURA Stock Price, Quote & Chart | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Vanguard reports 5.01% stake in Kura Oncology (NASDAQ: KURA) - Stock Titan
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Kura Oncology (KURA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Moody Aldrich Partners LLC Buys New Position in Kura Oncology, Inc. $KURA - MarketBeat
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML - marketscreener.com
Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML - BioPharma APAC
Kura rises after early-stage trial data for kidney cancer therapy - MSN
Kura Oncology shares jump on encouraging kidney cancer trial results - MSN
KURA Financials: Income Statement, Balance Sheet & Cash Flow | Kura Oncology Inc - Stock Titan
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 earnings call transcript - MSN
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell CarcinomaSlideshow (NASDAQ:KURA) 2026-04-21 - Seeking Alpha
Barclays Sticks to Their Buy Rating for Kura Oncology (KURA) - The Globe and Mail
Kura Oncology: Poised For A Lift With Combinations (NASDAQ:KURA) - Seeking Alpha
Is Kura Oncology (KURA) stock expanding in volatility (+1.45%) 2026-04-20Community Sell Signals - Cổng thông tin điện tử tỉnh Tây Ninh
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data - TradingView
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last? - Yahoo Finance
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How The Kura Oncology (KURA) Narrative Is Shifting With Komzifti Launch And New Analyst Targets - Yahoo Finance
Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results - Sahm
KURA: Promising Results from Kura Oncology's Trial on ccRCC Trea - GuruFocus
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Kura Oncology (NASDAQ:KURA) Stock Price Up 9.7%Time to Buy? - MarketBeat
Kura Oncology (KURA) Shows Promising Phase 1 Trial Results for K - GuruFocus
Kura Oncology shares jump on positive kidney cancer trial data By Investing.com - Investing.com Canada
Kura Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib - The Manila Times
Kura Oncology Announces Promising Preliminary Data on Darlifarnib in Combination with Cabozantinib for ccRCC Patients Previously Treated with Cabozantinib - Quiver Quantitative
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients ... - Enidnews.com
Kura Oncology Reports Darlifarnib Plus Cabozantinib - GlobeNewswire
Kura Oncology, Inc. (KURA) Stock Analysis: A 247% Upside Potential Beckons Investors - DirectorsTalk Interviews
Kura kidney cancer combo shrank tumors in 75% after cabozantinib - Stock Titan
Kura Oncology (NASDAQ:KURA) Raised to Strong-Buy at Lake Street Capital - MarketBeat
Lake Street initiates coverage of Kura Oncology (KURA) with buy recommendation - MSN
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):